- Home
- TTNP vs SILO Comparison
TTNP vs SILO Comparison
Compare TTNP & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- SILO
- Stock Information
- Founded
- TTNP 1991
- SILO 2010
- Country
- TTNP United States
- SILO United States
- Employees
- TTNP N/A
- SILO N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- SILO Apparel
- Sector
- TTNP Health Care
- SILO Consumer Discretionary
- Exchange
- TTNP Nasdaq
- SILO Nasdaq
- Market Cap
- TTNP 5.4M
- SILO 5.9M
- IPO Year
- TTNP 1996
- SILO N/A
- Fundamental
- Price
- TTNP $4.23
- SILO $0.61
- Analyst Decision
- TTNP
- SILO
- Analyst Count
- TTNP 0
- SILO 0
- Target Price
- TTNP N/A
- SILO N/A
- AVG Volume (30 Days)
- TTNP 92.5K
- SILO 307.3K
- Earning Date
- TTNP 08-14-2025
- SILO 08-13-2025
- Dividend Yield
- TTNP N/A
- SILO N/A
- EPS Growth
- TTNP N/A
- SILO N/A
- EPS
- TTNP N/A
- SILO N/A
- Revenue
- TTNP N/A
- SILO $72,102.00
- Revenue This Year
- TTNP N/A
- SILO $1.86
- Revenue Next Year
- TTNP N/A
- SILO N/A
- P/E Ratio
- TTNP N/A
- SILO N/A
- Revenue Growth
- TTNP N/A
- SILO N/A
- 52 Week Low
- TTNP $3.03
- SILO $0.41
- 52 Week High
- TTNP $6.43
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- TTNP 45.73
- SILO 44.10
- Support Level
- TTNP $3.58
- SILO $0.59
- Resistance Level
- TTNP $4.45
- SILO $0.67
- Average True Range (ATR)
- TTNP 0.37
- SILO 0.04
- MACD
- TTNP -0.08
- SILO -0.01
- Stochastic Oscillator
- TTNP 36.93
- SILO 14.33
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.